Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diphtheria Toxin Mutant Protein (CRM197)
- Target
- CRM197
- Molecular classification
- Toxin, Mutant Protein, Carrier Protein
01
Overview
CRM197 is a genetically detoxified, non-toxic mutant of diphtheria toxin. It is widely used as a carrier protein in conjugate vaccines to enhance the immunogenicity of polysaccharides and haptens. It differs from wild-type diphtheria toxin by a single point mutation (G52E), which abolishes toxicity while preserving the structure necessary for conjugation. Beyond vaccines, it can bind HB-EGF and is being explored for drug delivery applications.
- Other names
- Cross-Reactive Material 197Corynebacterium diphtheriae CRM197 protein
02
Mechanism of action
Loss of ADP-ribosyltransferase activity eliminates toxicity, retains ability to bind and internalize via HB-EGF receptor.
03
Biological functions
Carrier protein for conjugate vaccinesHB-EGF inhibitionDrug delivery (experimental)
04
Disease associations
Infection (vaccine preventable diseases)Cancer (potential HB-EGF related)
05
Safety considerations
Potential toxicity in yeast or mammalian cells under specific conditionsImmunogenicity (potential for anti-CRM197 antibodies)Hypersensitivity
06
Interacting drugs
Prevnar (pneumococcal vaccine)
1 more in the full profile.
Beyond the preview
Go deeper on Diphtheria Toxin Mutant Protein (CRM197).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diphtheria Toxin Mutant Protein (CRM197).